JPRN-UMIN000049776
Recruiting
未知
Role and mechanism of type I interferon in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis - Role and mechanism of type I interferon in the pathogenesis of anti-MDA5 antibody-positive dermatomyositis
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Anti-MDA5 antibody-positive dermatomyositis
- Sponsor
- Chiba University
- Enrollment
- 150
- Status
- Recruiting
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •1\) Patients or health controls who cannot give consent. 2\) Patients or health controls who are unable to collect specimens. 3\) Patients or health controls who are eligible to opt\-out and who have requested to opt\-out 4\) Patients or health controls with other diseases or conditions that are considered inappropriate for this study. 5\) Healthy controls with a history of connective tissue disease.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Not yet recruiting
Not Applicable
The Role of Type I Interferon in Interstitial Lung DiseaseConnective TIssue Diseasesrheumatic diseases10003816NL-OMON56690Erasmus MC, Universitair Medisch Centrum Rotterdam120
Active, not recruiting
Phase 1
Antiviral and Immunomodulatory Interferon-Beta in high-risk COVID-19 patientsSARS-CoV 2 infection characterized by a National Early Warning Score lower or equal to 2 and symptoms present for less than 7 daysMedDRA version: 23.0Level: LLTClassification code 10053983Term: Corona virus infectionSystem Organ Class: 100000004862MedDRA version: 20.0Level: PTClassification code 10070255Term: Coronavirus test positiveSystem Organ Class: 10022891 - InvestigationsTherapeutic area: Diseases [C] - Virus Diseases [C02]EUCTR2020-003872-42-ITIstituto di Farmacologia Traslazionale - CNR60
Active, not recruiting
Not Applicable
Bio-molecular effects of interferon-beta and d-vitamin association - VITAD-2010EUCTR2010-023677-19-ITAZIENDA OSPEDALIERA S. LUIGI GONZAGA
Completed
Phase 3
The effect of Combination Peg interferon –alpha to Tenofovir versus each one of the treatment modalities alone on Patients with HBeAg-negative: A randomized clinical trialIRCT20181113041635N1vice presidency for siences and technology , Iran national silences foundation60
Completed
Phase 3
Comparison of Interferon-beta-1a and Dexamethasone on hospitalized patients with Covid-19.IRCT20150622022869N9Yasouj University of Medical Sciences176